Artificial Intelligence
Selvita to acquire Fidelta from Galapagos
-Strengthening Selvita’s position as one of the largest preclinical contract research organizations in Europe –
Mechelen, Belgium and Krakow, Poland – 23 November 2020, 22.15 CET – Galapagos NV [Euronext & NASDAQ: GLPG] and Selvita S.A. [WSE: SLV] – announced today that they have signed an agreement under which Selvita will acquire 100% of the outstanding shares in Fidelta d.o.o. for an enterprise value of € 31.2M plus the customary adjustments for net cash and working capital.
Fidelta is a contract research organization within the Galapagos Group of companies, with core scientific competences in inflammation, fibrosis, and anti-infectives. It currently employs 181 employees, including over 150 highly experienced scientists, providing integrated drug discovery services in the biotech and pharmaceutical industry, with a proven track record of accomplished laboratory projects over many years. Fidelta is located in state-of-the art R&D facilities in Zagreb, Croatia which offer almost 6,000 m2 of research space. The transaction is subject to customary closing conditions and is expected to close on the 4th of January 2021.
Galapagos is a fully integrated biopharmaceutical company with a deep pipeline of novel mechanism of action candidates and commercial operations in Europe; as such, the CRO activities offered by Fidelta no longer fit with its strategy.
Upon completion of the acquisition, Fidelta will be fully consolidated under the Selvita Group, and will continue to operate under the Fidelta name. More comprehensive offering and opening of new growth opportunities
The scope of services provided by Fidelta is complementary to Selvita’s offerings and will enable Selvita to build a competitive advantage in business areas such as DMPK, in vivo pharmacology, and toxicology. Selvita will also increase its scale of operations within medicinal chemistry and in vitro pharmacology, resulting in significant strengthening of its market position.
Fidelta’s therapeutic areas of expertise align with current market trends, as infectious diseases, inflammation, and fibrosis are all areas of core expertise for Fidelta and are becoming increasingly major areas of interest for pharma companies due to the significant and unmet medical needs.
“We are thrilled to announce our acquisition of Fidelta. This is a perfect fit for us: an extensively experienced organization, with a full range of in-house drug discovery capabilities and an established track record of clinical candidate delivery,” says Boguslaw Sieczkowski, Chief Executive Officer at Selvita. “With this acquisition, we are not only executing our strategy announced this year, but we’re actually taking a leap in both the scope of our services portfolio and the scale of business. It is a transformative moment in the history of Selvita.”
“The scientific knowledge, the business acumen, and the focus and commitment of the team at Fidelta are second to none. I would like to thank the Fidelta team for the excellent collaboration over the years. I’m sure they will thrive under the Selvita umbrella. We will continue part of our discovery work with Fidelta, so we will benefit from that,” says Onno van de Stolpe, CEO of Galapagos. “We are very happy to take this big and logical step in the further development of Fidelta, and together with Selvita, to strengthen our presence on the market. Bringing together these two companies will allow us to keep a high level of quality and offer an even more integrated approach in services that we provide to our clients,” says Adrijana Vinter, Managing Director of Fidelta.
Transaction structure and its value potential
Over the years, Fidelta has transformed from an internal R&D department into a profitable external CRO delivering strong growth. Fidelta reported revenues of € 17.4M and an EBITDA of € 2.6M in 2019. Full year 2020 is on track to become a record year for Fidelta; in the first 9 months Fidelta reported revenues of € 17.2M, and an operating profit of € 4.4M.
Fidelta possesses a diverse revenue base, including cooperation with a significant number of big pharma and biotech customers. The acquisition will add to Selvita’s revenues growth and make a significant contribution to its EBITDA.
About Selvita About Galapagos Contacts Selvita
Media & Investors: Contacts Galapagos
Investors: Sofie Van Gijsel Media: Anna Gibbins Forward-looking statements Selvita We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based. Forward-looking statements Galapagos
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, that are subject to risks, uncertainties and other factors that could cause actual results to differ materially from those referred to in the forward-looking statements and, therefore, the reader should not place undue reliance on them. These risks, uncertainties and other factors include, without limitation, the risk that parties would be unable to complete the transaction within the currently foreseen timelines or at all, the risk that Galapagos’ expectations regarding Fidelta’s results for the full year 2020 and regarding the continued growth of Fidelta may be incorrect, the risk that Galapagos’ expectations regarding Fidelta’s future service performance for Galapagos would be incorrect, as well as, those risks and uncertainties identified in our Annual Report on Form 20-F for the year ended 31 December 2019 and our subsequent filings with the SEC. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. The forward-looking statements contained herein are based on management’s current expectations and beliefs and speak only as of the date hereof, and Galapagos makes no commitment to update or publicly release any revisions to forward-looking statements in order to reflect new information or subsequent events, circumstances or changes in expectations.
Attachment
Selvita is a preclinical Contract Research Organization providing multidisciplinary support in resolving the unique challenges of research within area of drug discovery, regulatory studies, as well as research and development.
The Company was established in 2007 and currently employs over 550 professionals, of which over 1/3 hold a PhD title. Selvita is headquartered in Krakow, Poland, with a second research site in Poznan, Poland and international offices located in Cambridge, MA and South San Francisco, in the U.S., as well as in Cambridge, UK. Selvita is a major shareholder in Ardigen – bioinformatics company harnessing advanced Artificial Intelligence methods for novel precision medicine.
Selvita has a proven track record of successfully completed projects and customers in 40 countries. The majority of Company revenues come from pharma, biotech, chemical and agrochemical companies from the U.S. and Europe. Selvita is listed on the Warsaw Stock Exchange (WSE:SLV). More information at www.selvita.com.
Galapagos (Euronext & NASDAQ: GLPG) discovers and develops small molecule medicines with novel modes of action, several of which show promising patient results and are currently in late-stage development in multiple diseases. The company’s pipeline comprises early discovery through to Phase 3 programs in inflammation, fibrosis, and other indications. Galapagos’ ambition is to become a leading global biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines. More information at www.glpg.com.
Natalia Baranowska
+48 784 069 418
[email protected]
Elizabeth Goodwin
VP Investor Relations
+1 781 460 1784
Senior Director Investor Relations
+32 485 19 14 15
[email protected]
Carmen Vroonen
Global Head of Communications & Public Affairs
+32 473 824 874
Senior Director Therapeutic Areas Communications
+44 7717 801900
[email protected]
Information set forth in this press release contains forward-looking statements, which involve a number of risks and uncertainties. The forward-looking statements contained herein represent the judgement of Selvita as of the date of this press release. Such forward-looking statements are neither promises nor guarantees but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. These risks, uncertainties and other factors include, without limitation, the risk that parties would be unable to complete the transaction within the currently foreseen timelines or at all, the risk that Selvita’s expectations regarding Fidelta’s results for the full year 2020 and regarding the continued growth of Fidelta may be incorrect, the risk that Selvita’s expectations regarding Fidelta’s future service performance for Selvita would be incorrect.
Artificial Intelligence
MGI Tech and SeqOne Partner to Advance End-to-end Genomic Analysis
PARIS, June 17, 2024 /PRNewswire/ — MGI (MGI Tech Co., Ltd. or its subsidiaries, together referred to MGI), a company committed to building core tools and technologies that drive innovation in life science, today announced the collaboration with SeqOne, a leading provider of AI-driven genomic decision support software, to develop and validate end-to-end genomic analysis solutions from sample to report tailored to the needs of Human Genetics and Pathology labs worldwide.
This collaboration between MGI and SeqOne encompasses three distinct initiatives:
Validating an end-to-end, automated, cost-effective solution for HRD signature with MGI DNBSEQ-G99
The collaboration between a Pathology Reference Lab in Spain, Agilent Technologies, MGI, and SeqOne aims to technically validate a routine workflow leveraging Agilent panels, Magnis lib prep automation, MGI DNBSEQ-G99, and SeqOne somaHRD, a clinically validated HRD signature solution, on 96 samples.
This end-to-end solution for pathology molecular labs will enable high-quality, efficient, and flexible HRD testing worldwide, including Genomic Instability score and BRCA testing.
Enabling and validating SeqOne tertiary analysis solution compatible with MGI Megabolt for Germline Panels, Whole Exome and Whole Genome
MegaBOLT bioinformatics analysis accelerator, self-developed and MPS-concentrated hardware accelerating system by MGI, is set to ensure seamless integration and compatibility with SeqOne’s AI-powered variants identification and analysis solution.
The collaboration aims to combine MegaBOLT and the SeqOne Platform to deliver a versatile, cost-effective, intuitive, and time-saving solution from sample to report, particularly attractive for high-throughput Human Genetics labs.
Validating SeqOne CE-IVD Platform for Germline and Somatic analysis for use with MGI sequencers in routine diagnostics
This technical validation project aims to evaluate the compatibility of the SeqOne Platform with MGI sequencing data. It will validate variant calling performances on a set of reference control samples in terms of QC, sensitivity and precision.
“We are thrilled to announce our collaboration with SeqOne. By combining MGI’s cutting-edge sequencing technology with SeqOne’s innovative genomic analysis Platform, we are poised to deliver real insights and solutions for personalized healthcare,” said Dr. Yong Hou, General Manager of MGI Europe and Africa. “This collaboration underscores our commitment to advancing genomic research and providing clinicians with the tools they need to offer tailored treatments to their patients.”
“This partnership with MGI strongly supports SeqOne’s mission to broaden access to sophisticated genomic analysis, aiming to improve healthcare outcomes,” said Martin Dubuc, CEO, SeqOne. “Molecular laboratories globally are exploring how MGI’s sequencing and bioinformatics technologies can advance next-generation sequencing (NGS) research and diagnostics. We are eager to integrate SeqOne’s CE-IVD Platform with MGI’s offerings, enhancing the quality, sensitivity, and precision of bioinformatic analyses.”
About MGI
MGI Tech Co., Ltd. (or its subsidiaries, together referred to MGI) is committed to building core tools and technologies that drive innovation in life science. Our focus lies in research & development, manufacturing, and sales of instruments, reagents, and related products in the field of life science and biotechnology. We provide real-time, multi-omics, and full spectrum of digital equipment and systems for precision medicine, agriculture, healthcare and various other industries. Founded in 2016, MGI has grown into a leader in life science, serving customers across six continents and have established research, manufacturing, training, and after-sales service facilities globally. MGI stands out as one of the few companies capable of independently developing and mass-producing clinical-grade gene sequencers with varying throughput capacities, ranging from Gb to Tb levels. With unparalleled expertise, cutting-edge products, and a commitment to global impact, MGI continues to shape the trajectory of life sciences into the future. To learn more, please visit https://en.mgi-tech.com/, LinkedIn, X, and YouTube.
About SeqOne
SeqOne is a fast-growing deep-tech company focused on turning genomic data into medically- actionable insights in oncology and rare and inherited diseases. Our vision is to make personalized healthcare a reality for every patient, everywhere. We are committed to democratizing access to advanced genomic insights, enabling labs of any size, in any location, to offer affordable personalized medicine solutions to patients at scale. We integrate cutting-edge AI and big data technologies to redefine genetic data analysis. Our CE-IVD Platform provides time saving, flexible, and cost-effective decision support, empowering decentralized laboratories worldwide to deliver precision diagnostics.The company has won numerous awards, including the iLab award and the ARC Cancer Foundation’s Hélène Stark prize. Investors include Elaia, IRDI Capital Investissement, Merieux Equity Partners, Omnes, and Software Club. To learn more, please visit www.seqone.com and Linkedin.
Logo – https://mma.prnewswire.com/media/2329841/MGI__Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/mgi-tech-and-seqone-partner-to-advance-end-to-end-genomic-analysis-302173987.html
Artificial Intelligence
Symphony Talent’s Award-Winning Full-Funnel Talent Acquisition Portfolio Earns Strategic Challenger Status on Fosway 9-Grid™ for Third Consecutive Year
NEW YORK and LONDON, June 17, 2024 /PRNewswire/ — Symphony Talent, a global leader in recruitment marketing technology and employer brand services, has been named a Strategic Challenger on the 2024 Fosway 9-Grid™ for Talent Acquisition for the third consecutive year, demonstrating Symphony Talent’s consistent dedication to providing cutting-edge solutions that drive game-changing results for talent acquisition teams worldwide.
“From rapidly evolving technologies to shifting candidate expectations, the TA industry faces many challenges,” says Sven Elbert, Head of Analyst Services at Fosway Group. “A full-funnel talent acquisition solution — that seamlessly aligns employer branding, technology and data analytics to the candidate journey — is essential to address these complexities. Symphony Talent provides a robust framework for meeting the diverse needs of complex, global enterprise-scale clients.”
Empowering TA Teams with Full-Funnel Solutions
Symphony Talent’s extensive portfolio of talent acquisition solutions, including its Brand and Creative Services, Programmatic Media Advertising, Career Sites, CRM, and Assessments, drive outstanding client results by addressing every stage of the talent acquisition funnel. Over 700 global clients leverage Symphony Talent’s innovative technologies and strategic expertise, achieving significant outcomes, such as:
Cutting administrative recruiting tasks by 65%Spending 70% less time managing media spendReducing time spent qualifying talent by 60%Decreasing cost per hire by 25%Filling open positions 30% fasterEnsuring quality hires with a 15% reduction in employee turnover”We are honored to be recognized as a Strategic Challenger on the Fosway 9-Grid™ for the third year in a row,” says Kermit Randa, CEO of Symphony Talent. “This achievement highlights our ongoing commitment to connect clients with innovative, high-impact solutions and data that empower them to navigate the complexities of today’s talent landscape and confidently convert candidates to co-workers.”
Highlights of Symphony Talent’s Achievement:
Innovation and Leadership: Symphony Talent’s continuous recognition as a Strategic Challenger is a testament to its unwavering commitment to innovation and leadership in the talent acquisition industry. The company’s comprehensive suite of solutions, including the award-winning SFX platform, integrates brand and creative services with recruitment marketing technology to streamline the hiring process and enhance candidate experience.Client-Centric Approach: Symphony Talent’s focus on understanding and addressing its clients’ evolving needs has been pivotal in maintaining its strategic position. Symphony Talent ensures clients achieve tangible and measurable outcomes by offering personalized support, detailed implementation schedules, and optimization workgroups.Adaptation to Market Trends: With a deep understanding of the current market dynamics and the challenges faced by talent acquisition teams, Symphony Talent has continuously adapted its offerings to meet these demands. This includes leveraging AI and automation to enhance productivity and providing data-driven insights to optimize recruitment strategies.About the Fosway 9-Grid™
Fosway Group is Europe’s #1 HR industry analyst. The Fosway 9-Grid™ provides a unique assessment of the principal learning and talent supply options available to organisations in EMEA. The analysis is based on extensive independent research and insights from Fosway’s Corporate Research Network of over 250 organisations, including BP, HSBC, PwC, RBS, Sanofi, Shell, and Vodafone. Visit the Fosway website at www.fosway.com.
About Symphony Talent
Symphony Talent is a recruitment marketing technology and employer brand services company that helps talent acquisition teams execute strategic, innovative candidate interactions. Our award-winning, synergistic technology and brand solutions are designed to deliver outcomes — from reach to retention — that unlock a competitive advantage for clients across the globe, including the world’s leading brands. Visit symphonytalent.com to learn more.
Logo – https://mma.prnewswire.com/media/2287879/ST_Logo_Single_Line_Full_Color__12_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/symphony-talents-award-winning-full-funnel-talent-acquisition-portfolio-earns-strategic-challenger-status-on-fosway-9-grid-for-third-consecutive-year-302173377.html
Artificial Intelligence
Darwinbox named as a Customers’ Choice in the 2024 Gartner® Peer Insights™ Voice of the Customer for Cloud HCM Suites Report for Enterprises with 1,000+ Employees
DUBAI, UAE, June 17, 2024 /PRNewswire/ — Darwinbox, a global leader in cloud-based HCM solutions, today announced that it has been distinguished as a Customers’ Choice in the 2024 Gartner® Peer Insights™ Voice of the Customer for Cloud HCM Suites for 1,000+ Employee Enterprises.
The Gartner® Peer Insights™ Customers’ Choice distinction is based on feedback and ratings from end-user professionals with experience using the product or service. As of 31 January 2024, Darwinbox received an overall rating of 4.8 out of 5 stars across 141 reviews.
“We believe this distinction, for the third consecutive year, reflects our unwavering commitment to our customers and their success, as well as our dedication to excellence and innovation in the HCM space,” says Jayant Paleti, co-founder, Darwinbox.
Darwinbox has been named a Customers’ Choice for both Large Enterprise (1B – 10B USD) and Midsize Enterprise (50M – 1B USD) segments, showcasing its robust capabilities in handling large-scale operations and its widespread appeal across various business sizes. This recognition underscores the platform’s popularity, driven by its powerful configurability, intuitive design, and agility. An impressive 98% of customers rated Darwinbox 4-stars or higher, highlighting the overwhelming satisfaction with the product.
Furthermore, Darwinbox is recognized as the most customer-friendly enterprise-grade HCM solution globally. The platform distinguishes itself through its ease of implementation and integration, prompt vendor responses, and exceptional technical support, demonstrating Darwinbox’s dedication to quick service and client satisfaction. Notably, 94% of its customers have expressed their willingness to recommend Darwinbox, demonstrating its significant impact and reliability in the enterprise tech landscape.
“What I love is when we need support, the customer service is top-notch – always responsive, solution makers, and always helpful,” HR Business Partner, Media Industry
“Darwinbox has been able to cater to our needs given our diverse business structures and differences in processes,” HR Lead, Manufacturing Sector
Read more reviews
About Darwinbox:
Darwinbox is a leading SaaS-based HR technology platform, empowering organisations to automate HR processes and elevate the employee experience. Rated the highest globally among HCM players on Gartner’s customer review platform, Peer Insights, Darwinbox is trusted by 900+ global enterprises with more than 2.5 million employees spread across 116+ countries.
Photo: https://mma.prnewswire.com/media/2438686/Darwinbox_Voice_of_the_Customer.jpg
View original content:https://www.prnewswire.co.uk/news-releases/darwinbox-named-as-a-customers-choice-in-the-2024-gartner-peer-insights-voice-of-the-customer-for-cloud-hcm-suites-report-for-enterprises-with-1-000-employees-302173015.html
-
Artificial Intelligence7 days ago
ADP Rings NASDAQ Opening Bell Celebrates 75 Years at the Forefront of Payroll & HR Innovation
-
Artificial Intelligence3 days ago
Borderless AI & Cohere team up to build a custom-trained AI model for HR professionals, taking on Deel and Remote.com
-
Artificial Intelligence7 days ago
TraceLink Partners with Genpact to Expand Delivery of Digital Supply Chain Innovation for Healthcare and Life Sciences Sectors
-
Artificial Intelligence7 days ago
Empowering data practitioners will help shape generative AI deployment for enterprise, says new MIT Technology Review Insights research report
-
Uncategorized6 days ago
Hughes Europe Expands into Military, Defence & Government Sectors with Launch of Konnect VHTS Services in Collaboration with Telespazio
-
Uncategorized4 days ago
AI Could Transform UK’s Public Finances as Labour Touts Gains
-
Artificial Intelligence3 days ago
LoRa and LoRaWAN IoT Market worth $32.7 billion by 2029- Exclusive Report by MarketsandMarkets™
-
Artificial Intelligence3 days ago
Complyport’s new AI tool – ViCA.Chat – set to revolutionise compliance support services